Telix Pharmaceuticals (TLX) H2 2025 earnings summary

Executive summary

• Achieved 56% revenue growth to $804 million in FY 2025, marking the third consecutive year of double-digit growth, driven by precision medicine and successful product launches.

• Precision Medicine revenue reached $622 million, up 22% year-over-year, with Illuccix and Gozellix as key contributors.

• Maintained strong gross margins and invested over $500 million into R&D, commercial expansion, and infrastructure, all self-funded from operations.

• Focused on three 2026 priorities: growing core business, launching Pixclara and Zircaix, and advancing pivotal clinical programs.

• Positioned for further global expansion, especially in Europe and Asia, with new product launches and reimbursement milestones.

Financial highlights

• Revenue reached $804 million, up 56% year-over-year, with precision medicine revenue up 22%.

• EBITDA improved 25% to $216 million, and adjusted EBITDA was $39.5 million, in line with consensus.

• Gross margin held steady at 53%, with precision medicine gross margin at 64%.

• Ended the year with $142 million in cash, after significant R&D and strategic investments.

• Operating profit was $30 million, while net loss after tax was $7 million, impacted by increased finance costs and R&D investment.

Outlook and guidance

• FY 2026 revenue guidance is $950–$970 million, with ~25% growth expected in precision medicine and a full year of RLS revenue.

• R&D investment for FY 2026 is guided at $200–$240 million, focused on the therapeutics pipeline and dependent on clinical milestones.

• Strategic priorities include launching Pixclara and Zircaix in the U.S., expanding Illuccix globally, and advancing five high-value clinical programs.

• Strategy is to reinvest earnings for long-term value, not near-term profit maximization.